TY - JOUR T1 - Fatty Acid Synthase (FAS) is a Marker of Increased Risk of Recurrence in Lung Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 4169 LP - 4174 VL - 24 IS - 6 AU - PAOLO VISCA AU - VALERIA SEBASTIANI AU - CLAUDIO BOTTI AU - MARIA GRAZIA DIODORO AU - ROBERTO PASQUALI LASAGNI AU - FRANCESCA ROMAGNOLI AU - ALESSIA BRENNA AU - BARBARA CAPEZZONE DE JOANNON AU - RAFFAELE PERRONE DONNORSO AU - GIUSEPPE LOMBARDI AU - PIERO LUIGI ALO Y1 - 2004/11/01 UR - http://ar.iiarjournals.org/content/24/6/4169.abstract N2 - Background: We explored the expression of Fatty Acid Synthase (FAS) in lung carcinomas and its association with clinico-pathological features and prognosis. FAS is a recently discovered molecule involved in the energy supply of normal cells. FAS is also overexpressed in neoplastic tissues because of their increased necessity for energy. Patients and Methods: One hundred and six patients with non-small cell lung carcinoma were followed-up for an average period of 5 years. FAS expression was detected immunohistochemically. Results: FAS staining was observed in 61 out of 106 cases (57.54%). Statistical analysis revealed that FAS had an overall low prognostic value (p=0.14), while FAS-negative expression in stage I patients showed a trend for better survival (p=0.10). PTNM stage (p<0.0001) was the only significant prognostic marker for overall survival. Conclusion: FAS is a reliable marker of low-stage clinically aggressive lung carcinomas. The determination of FAS expression in lung carcinomas may stratify patients and determine therapeutic approaches for their care. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -